Log in

ImmunoGen Stock Forecast, Price & News

+0.18 (+5.14 %)
(As of 09/25/2020 12:00 AM ET)
Today's Range
Now: $3.68
50-Day Range
MA: $3.80
52-Week Range
Now: $3.68
Volume1.19 million shs
Average Volume2.73 million shs
Market Capitalization$642.31 million
P/E RatioN/A
Dividend YieldN/A
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. ImmunoGen, Inc. has collaborations with Roche, Amgen/Oxford BioTherapeutics, sanofi-aventis U. S. LLC, Biotest AG, Bayer HealthCare AG, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Fusion Pharmaceuticals Inc., Debiopharm International SA, Jazz Pharmaceuticals Ireland Limited, and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Read More
ImmunoGen logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.38 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:IMGN



Sales & Book Value

Annual Sales$82.27 million
Book Value($0.51) per share


Net Income$-104,130,000.00


Market Cap$642.31 million
Next Earnings Date11/6/2020 (Estimated)
+0.18 (+5.14 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for IMGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

ImmunoGen (NASDAQ:IMGN) Frequently Asked Questions

How has ImmunoGen's stock price been impacted by Coronavirus (COVID-19)?

ImmunoGen's stock was trading at $3.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IMGN shares have increased by 9.2% and is now trading at $3.68.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of ImmunoGen?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ImmunoGen

When is ImmunoGen's next earnings date?

ImmunoGen is scheduled to release its next quarterly earnings announcement on Friday, November 6th 2020.
View our earnings forecast for ImmunoGen

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) posted its quarterly earnings data on Friday, July, 31st. The biotechnology company reported ($0.14) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.18) by $0.04. The biotechnology company earned $15.03 million during the quarter, compared to analysts' expectations of $14.29 million.
View ImmunoGen's earnings history

What guidance has ImmunoGen issued on next quarter's earnings?

ImmunoGen updated its FY 2020 Pre-Market earnings guidance on Friday, July, 31st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $60-65 million, compared to the consensus revenue estimate of $63.12 million.

What price target have analysts set for IMGN?

4 analysts have issued 1 year price objectives for ImmunoGen's stock. Their forecasts range from $9.00 to $12.00. On average, they anticipate ImmunoGen's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 185.3% from the stock's current price.
View analysts' price targets for ImmunoGen

Are investors shorting ImmunoGen?

ImmunoGen saw a decline in short interest in September. As of September 15th, there was short interest totaling 15,700,000 shares, a decline of 10.1% from the August 31st total of 17,470,000 shares. Based on an average daily volume of 2,170,000 shares, the days-to-cover ratio is presently 7.2 days.
View ImmunoGen's Short Interest

Who are some of ImmunoGen's key competitors?

What other stocks do shareholders of ImmunoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), Immunomedics (IMMU), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Advanced Micro Devices (AMD), AbbVie (ABBV), Dynavax Technologies (DVAX), Opko Health (OPK) and Energy Transfer LP Unit (ET).

Who are ImmunoGen's key executives?

ImmunoGen's management team includes the following people:
  • Mr. Mark J. Enyedy, Pres, CEO, Interim Principal Financial Officer & Director (Age 55)
  • Dr. Richard J. Gregory, Exec. VP & Chief Scientific Officer (Age 61)
  • Mr. Craig Barrows, Exec. VP, Gen. Counsel & Sec. (Age 64)
  • Dr. Anna Berkenblit, VP & Chief Medical Officer (Age 49)
  • Mr. David G. Foster, VP of Fin. & Chief Accounting Officer

What is ImmunoGen's stock symbol?

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

Who are ImmunoGen's major shareholders?

ImmunoGen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.54%), Goldman Sachs Group Inc. (0.99%), Charles Schwab Investment Management Inc. (0.66%), Two Sigma Advisers LP (0.63%), Pinnacle Associates Ltd. (0.62%) and Nuveen Asset Management LLC (0.56%). Company insiders that own ImmunoGen stock include Anna Berkenblit, Craig Barrows, David G Foster, Mark Alan Goldberg, Mark J Enyedy, Richard J Gregory and Thomas Ryll.
View institutional ownership trends for ImmunoGen

Which major investors are selling ImmunoGen stock?

IMGN stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Nuveen Asset Management LLC, Federated Hermes Inc., Bank of America Corp DE, UBS Group AG, Healthcare of Ontario Pension Plan Trust Fund, Russell Investments Group Ltd., and Alps Advisors Inc.. Company insiders that have sold ImmunoGen company stock in the last year include Craig Barrows, David G Foster, Mark J Enyedy, and Thomas Ryll.
View insider buying and selling activity for ImmunoGen

Which major investors are buying ImmunoGen stock?

IMGN stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Assenagon Asset Management S.A., Skandinaviska Enskilda Banken AB publ, Principal Financial Group Inc., Principal Financial Group Inc., HighTower Advisors LLC, Hussman Strategic Advisors Inc., and Two Sigma Advisers LP.
View insider buying and selling activity for ImmunoGen

How do I buy shares of ImmunoGen?

Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ImmunoGen's stock price today?

One share of IMGN stock can currently be purchased for approximately $3.68.

How big of a company is ImmunoGen?

ImmunoGen has a market capitalization of $642.31 million and generates $82.27 million in revenue each year. The biotechnology company earns $-104,130,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. ImmunoGen employs 296 workers across the globe.

What is ImmunoGen's official website?

The official website for ImmunoGen is www.immunogen.com.

How can I contact ImmunoGen?

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-895-0600 or via email at [email protected]

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.